This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ganesh, S. K. Articles by Nabel, E. G. Search for Related Content PubMed PubMed Citation Articles by Ganesh, S. K. Articles by Nabel, E. G. Related Collections Clinical genetics Restenosis Restenosis Genomics Smooth muscle proliferation and differentiation Catheter-based coronary interventions: stents Genetics of cardiovascular disease Mechanism of atherosclerosis/growth factors

(Circulation. 2005;112:2378-2379.)
© 2005 American Heart Association, Inc.

Editorial

Genomics of In-Stent Restenosis

Early Insights Into a Complex Disease

Santhi K. Ganesh, MD; Elizabeth G. Nabel, MD

From the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.

Correspondence to Elizabeth G. Nabel, MD, National Heart, Lung, and Blood Institute Bldg 31, Room 5A52, 31 Center Dr, Bethesda, MD 20892. E-mail enabel@nih.gov

Key Words: Editorials • atherosclerosis • genes • genetics • restenosis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Inflammation is a key component of atherosclerosis. Abundant preclinical data support the hypothesis that atherosclerosis is a chronic inflammatory disorder.^1,2 Indeed, clinical trial data now provide evidence that inflammation, as reflected in serum markers such as C-reactive protein and interleukin-6, is a strong risk factor for the development and progression of atherosclerosis.^3,4 The role of genetic factors in determining a predisposition or susceptibility to inflammation that exacerbates atherosclerosis is not fully known.

Article p 2417

In-stent restenosis occurs after the deployment of an intravascular stent within an atherosclerotic lesion. The fibroproliferative response to this vascular "injury" typically develops within the first 9 months postprocedure. The response to injury follows a continuum in human arteries; some degree of cell proliferation occurs in all patients and can be thought of as a wound-healing process. In some individuals, however, the wound healing becomes excessive, leading to exuberant vascular smooth muscle cell growth and extracellular matrix synthesis, and encroachment on the arterial lumen, and resulting in a recurrence of clinical symptoms. Molecular and genetic studies suggest that cell cycle proteins, growth factors, and inflammatory cytokines regulate this process.⁵ Drug-eluting stents have dramatically reduced the prevalence of in-stent restenosis because of the local treatment of the fibroproliferation with 2 drugs, sirolimus and paclitaxel, which have antiproliferative and antiinflammatory properties.^6,7 What is not known, however, is whether there is a genetic susceptibility that determines a patient’s response to stent deployment and development of in-stent restenosis.

In this issue of Circulation, Monraats et al investigate the . . . [Full Text of this Article]

This article has been cited by other articles:

				T. Matsumoto and P. M. Hwang Resizing the Genomic Regulation of Restenosis Circ. Res., June 8, 2007; 100(11): 1537 - 1539. [Full Text] [PDF]

				D. Torella, A. Curcio, C. Gasparri, V. Galuppo, D. D. Serio, F. C. Surace, A. L. Cavaliere, A. Leone, C. Coppola, G. M. Ellison, et al. Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2935 - H2943. [Abstract] [Full Text] [PDF]